Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT
- PMID: 12069959
- PMCID: PMC127309
- DOI: 10.1128/AAC.46.7.2087-2094.2002
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT
Abstract
We sequenced and phylogenetically analyzed the reverse transcriptase (RT) region of five human immunodeficiency virus type 1 isolates from treatment-naive Ethiopian émigrés to Israel. Heteroduplex mobility assays were performed to confirm the clade C status of env genomic regions. The RT sequences showed that the strains clustered phylogenetically with clade C viruses, and a KVEQ-specific motif of silent mutations (amino acids 65, 106, 138, and 161, respectively) at resistance sites was present in the polymerase region of all studied Ethiopian isolates and subtype C reference strains. In addition, many other silent mutations were observed in the clade C viruses at various resistance sites. In general, the Ethiopian isolates were more closely related genotypically to a clade C reference strain from Botswana (southern Africa) than to previously sequenced Ethiopian reference strains. Genotypic analysis showed that two Ethiopian isolates naturally harbored the mutations K70R and G190A associated with resistance to ZDV and nonnucleoside reverse transcriptase inhibitors, respectively. Phenotypic assays revealed that the K70R substitution in this context did not reduce susceptibility to ZDV, whereas the G190A substitution resulted in high-level resistance to nevirapine (NVP). Moreover, variants resistant to NVP, delavirdine (DLV), and efavirenz (EFV) were more rapidly selected at lower drug doses culture with clade C than with clade B wild-type isolates. In the case of subtype C, selection with NVP and/or EFV led to the appearance of several previously unseen mutations in RT, i.e., V106M and S98I, as well as other mutations that have been previously reported (e.g., K103N, V106A, V108I, and Y181C). After selection with DLV, a polymorphism, A62A, initially observed in the Ethiopian isolate 4762, mutated to A62V; the latter is a secondary substitution associated with multidrug resistance against nucleoside RT inhibitors. Phenotypic analysis of clade C mutants selected against NVP, DLV, and EFV revealed broad cross-resistance, particularly in regard to NVP and DLV. These findings suggest that RT genotypic diversity may influence the emergence of drug resistance.
Figures



Similar articles
-
Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.Antiviral Res. 2002 Nov;56(2):129-42. doi: 10.1016/s0166-3542(02)00100-6. Antiviral Res. 2002. PMID: 12367719
-
Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.AIDS Res Hum Retroviruses. 2006 Mar;22(3):289-93. doi: 10.1089/aid.2006.22.289. AIDS Res Hum Retroviruses. 2006. PMID: 16545016
-
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.J Virol. 2001 Jun;75(11):4999-5008. doi: 10.1128/JVI.75.11.4999-5008.2001. J Virol. 2001. PMID: 11333879 Free PMC article.
-
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.J Acquir Immune Defic Syndr. 2001 Mar 1;26 Suppl 1:S25-33. doi: 10.1097/00042560-200103011-00004. J Acquir Immune Defic Syndr. 2001. PMID: 11264999 Review.
-
Resistance to non-nucleoside reverse transcriptase inhibitors.In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 2. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 2. PMID: 21249773 Free Books & Documents. Review.
Cited by
-
Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem. 2012 Feb 24;287(9):6788-96. doi: 10.1074/jbc.M111.317883. Epub 2012 Jan 6. J Biol Chem. 2012. PMID: 22228771 Free PMC article.
-
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.Antimicrob Agents Chemother. 2007 Nov;51(11):3861-9. doi: 10.1128/AAC.00646-07. Epub 2007 Aug 27. Antimicrob Agents Chemother. 2007. PMID: 17724152 Free PMC article.
-
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.Antimicrob Agents Chemother. 2013 Nov;57(11):5649-57. doi: 10.1128/AAC.01536-13. Epub 2013 Sep 3. Antimicrob Agents Chemother. 2013. PMID: 24002090 Free PMC article.
-
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3. doi: 10.1128/AAC.01447-05. Antimicrob Agents Chemother. 2006. PMID: 16723586 Free PMC article.
-
Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.Retrovirology. 2010 Oct 12;7:85. doi: 10.1186/1742-4690-7-85. Retrovirology. 2010. PMID: 20939905 Free PMC article.
References
-
- Abebe, A., V. V. Lukashov, Pollakis, A. Kliphuis, A. L. Fontanet, J. Goudsmit, and T. F. Rinke de Wit. 2001. Timing of the HIV-1 subtype C epidemic in Ethiopia based on early virus strains and subsequent virus diversification. AIDS 15:1555-1561. - PubMed
-
- Adje, C., R. Cheingsong, T. H. Roels, C. Maurice, G. Djomand, W. Verbiest, K. Hertogs, B. Larder, B. Monga, M. Peeters, S. Eholie, E. Bissagene, M. Coulibaly, R. Respess, S. Z. Wiktor, T. Chorba, and J. N. Nkengasong. 2001. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 26:501-506. - PubMed
-
- Ayenie, S., B. O. Johansson, M. O. Salminen, P. Leinikki, A. Sonnerborg, D. Work-Zewdie, S. Britton, and O. Strannegard. 1991. HIV-1 in Ethiopia: phylogenetic divergence from other HIV-1 strains. Virus Genes 5:359-366. - PubMed
-
- Bacheler, L., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases